Zhang Jinzhong, Johnson Jennifer L, He Jing, Napolitano Gennaro, Ramadass Mahalakshmi, Rocca Celine, Kiosses William B, Bucci Cecilia, Xin Qisheng, Gavathiotis Evripidis, Cuervo Ana María, Cherqui Stephanie, Catz Sergio D
From the Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037.
the Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, California 92093-0734.
J Biol Chem. 2017 Jun 23;292(25):10328-10346. doi: 10.1074/jbc.M116.764076. Epub 2017 May 2.
The lysosomal storage disease cystinosis, caused by cystinosin deficiency, is characterized by cell malfunction, tissue failure, and progressive renal injury despite cystine-depletion therapies. Cystinosis is associated with defects in chaperone-mediated autophagy (CMA), but the molecular mechanisms are incompletely understood. Here, we show CMA substrate accumulation in cystinotic kidney proximal tubule cells. We also found mislocalization of the CMA lysosomal receptor LAMP2A and impaired substrate translocation into the lysosome caused by defective CMA in cystinosis. The impaired LAMP2A trafficking and localization were rescued either by the expression of wild-type cystinosin or by the disease-associated point mutant CTNS-K280R, which has no cystine transporter activity. Defective LAMP2A trafficking in cystinosis was found to associate with decreased expression of the small GTPase Rab11 and the Rab7 effector RILP. Defective Rab11 trafficking in cystinosis was rescued by treatment with small-molecule CMA activators. RILP expression was restored by up-regulation of the transcription factor EB (TFEB), which was down-regulated in cystinosis. Although LAMP2A expression is independent of TFEB, TFEB up-regulation corrected lysosome distribution and lysosomal LAMP2A localization in cells but not Rab11 defects. The up-regulation of Rab11, Rab7, or RILP, but not its truncated form RILP-C33, rescued LAMP2A-defective trafficking in cystinosis, whereas dominant-negative Rab11 or Rab7 impaired LAMP2A trafficking. Treatment of cystinotic cells with a CMA activator increased LAMP2A localization at the lysosome and increased cell survival. Altogether, we show that LAMP2A trafficking is regulated by cystinosin, Rab11, and RILP and that CMA up-regulation is a potential clinically relevant mechanism to increase cell survival in cystinosis.
由胱氨酸转运蛋白缺乏引起的溶酶体贮积病胱氨酸病,其特征是尽管采用了降低胱氨酸的疗法,但仍存在细胞功能障碍、组织衰竭和进行性肾损伤。胱氨酸病与伴侣介导的自噬(CMA)缺陷有关,但其分子机制尚不完全清楚。在此,我们展示了胱氨酸病肾近端小管细胞中CMA底物的积累。我们还发现CMA溶酶体受体LAMP2A定位错误,以及胱氨酸病中CMA缺陷导致底物转运到溶酶体受损。野生型胱氨酸转运蛋白的表达或疾病相关的点突变体CTNS-K280R(其没有胱氨酸转运活性)可挽救受损的LAMP2A运输和定位。发现胱氨酸病中LAMP2A运输缺陷与小GTP酶Rab11和Rab7效应器RILP的表达降低有关。用小分子CMA激活剂治疗可挽救胱氨酸病中缺陷的Rab11运输。转录因子EB(TFEB)上调可恢复RILP表达,TFEB在胱氨酸病中下调。尽管LAMP2A的表达独立于TFEB,但TFEB上调可纠正细胞中的溶酶体分布和溶酶体LAMP2A定位,但不能纠正Rab11缺陷。Rab11、Rab7或RILP的上调,但不是其截短形式RILP-C33,可挽救胱氨酸病中LAMP2A缺陷的运输,而显性负性Rab11或Rab7则损害LAMP2A运输。用CMA激活剂处理胱氨酸病细胞可增加LAMP2A在溶酶体的定位并提高细胞存活率。总之,我们表明LAMP2A运输受胱氨酸转运蛋白、Rab11和RILP调节,并且CMA上调是增加胱氨酸病细胞存活率的潜在临床相关机制。